The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.35
Bid: 13.20
Ask: 13.50
Change: 0.60 (4.71%)
Spread: 0.30 (2.273%)
Open: 12.75
High: 13.70
Low: 13.35
Prev. Close: 12.75
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

Wed, 13th Apr 2022 19:46

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Ediston Property Investment Co PLC - Edinburgh-based real estate investment company - Confirms sale of leisure asset at The Lanyard, Hartlepool, which is let to Mecca Bingo Ltd for GBP2.6 million, which is 16% above its most recent valuation at December 31.

----------

SulNOx Group PLC - London-based supplier of fuel conditioners - Receives certification for SulNOxEco Fuel Conditioner from Lloyd's Register Fuel Oil Bunker Analysis and Advisory Service. Lloyds found the fuel had minimal impact on ISO 8217 test parameters, without changing characteristics when added to machine fuel at the prescribed dosage rate. "Lloyd's Register is a highly respected and trusted international classification society and these results provide another significant landmark for SulNOx marine," says Nicholas Fairfax, non-executive director & Marine lead.

----------

Europa Oil & Gas (Holdings) PLC - Ireland and Morocco focused oil and gas exploration and production company - Records strongest interim performance since the first half of 2014, as revenue rises to GBP2.2 million in the six months to January 31, from GBP500,000 a year before. Swings to pretax profit of GBP700,000 from pretax loss of GBP700,000 a year prior. Attributes performance to its 30% interest in Wressle oil field in North Lincolnshire, which delivered beyond expectations.

----------

Value & Indexed Property Income Trust PLC - London-based investment manager for UK commercial properties - Says direct commercial property portfolio increases to GBP155.5 million at March 31, up from GBP110.5 million at September 30. VIP's property portfolio delivers total return of 8.8% over the six months to March 31, and 20% over the past year. " VIP is now almost fully invested after its transition to a predominantly property trust," it notes.

----------

McKay Securities PLC - South East and London-focused office property investor - Says board continues to unanimously recommend the takeover offer from Workspace Group PLC, following Tuesday's news that Canadian private equity firm Slate Asset Management did not intend to make an offer.

----------

Lekoil Ltd - oil and gas exploration and production company focused on Nigeria and West Africa - Notes the announcement from Lekoil Nigeria Ltd that it spuds the Otakikpo-4 well as part of its Phase 2 development at Otakikpo. Lekoil Nigeria also renews the Otakikpo offtake agreement with Shell Western Supply & Trading Ltd.

----------

IOG PLC - London-based gas and infrastructure operator with projects in the North Sea - Says fault at Blythe well "temporarily addressed" and the well reopened on Tuesday. "A further permanent modification on the Blythe platform has been designed and will be installed when materials are available. This permanent modification is not anticipated to involve material downtime," IOG says.

----------

Watchstone Group PLC - cash shell with remaining assets comprising litigation assets, contingent liabilities and cash - Says subsidiary WTGIL Ltd's dismissed in first-tier tribunal, with the ruling in favour of HMRC. Case concerns supplies of telematic devices or related services during VAT period 2014-2018. "WTGIL will consider the judgment with its advisers and counsel and decide on the next steps (if any) including whether to appeal to the Upper Tax Tribunal," it says.

----------

Open Orphan PLC - Notes announcement from Poolbeg Pharma PLC regarding numerous new investors expressing interest in acquiring up to GBP1.6 million of company's shares which are currently locked-up and held in trust by Croft Nominees Ltd, following the distribution in specie from Open Orphan PLC in June last year. "This arrangement has followed significant efforts to help widen the Poolbeg investor base and increase future liquidity, in order to ensure that the dividend in specie remains as beneficial as possible to shareholders of both Open Orphan and Poolbeg in the long-term," says Executive Chair Cathal Friel.

----------

Harland & Wolff Group Holdings PLC - Belfast-based offshore construction company - Says wholly-owned subsidiary Harland & Wolff (Arnish) Ltd wins fabrication contract at roll twelve Super Duplex Shells for the Hinkley C nuclear power project, to finish by the end of June. Arnish is on track to complete suction pile contract announced in November, and making progress to launch the first of eight boat landings for the Saipem contract. Cumulative value of projects is in the region of GBP2 million to GBP3 million.

----------

Bradda Head Lithium Ltd - North America-focused lithium development company - Raises GBP2.0 million through UK placing of 14.5 million shares at 13.5 pence, having received orders in excess of GBP6.6 million. This comes in addition to the North American fundraise, which raised GBP9.9 million through 73.2 shares at the same price. Non-executive director subscribed for 834,226 placing shares, bringing his total holding to 65.0 million shares, or 17% of Bradda's ordinary share capital.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.